RBC Capital raised the firm’s price target on Tandem Diabetes (TNDM) to $30 from $25 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that it continues to benefit from Mobi adoption and has the best in-class algorithm controlling its AID systems, also stating that Tandem’s global addressable market is expanding, positioning it for revenue upside.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $35 from $24 at Canaccord
- Tandem Diabetes price target raised to $21 from $18 at Mizuho
- Tandem Diabetes upgraded to Outperform from Neutral at Baird
- Citi ups Tandem target, adds ‘downside 90-day catalyst watch’
- Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley